GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's ...

An appeals court has opened another chapter in the long-running CRISPR patent saga. | An appeals court has opened another ...

The uncertainty around splitting up the business is only the latest in a series of strategic shake-ups at Galapagos in recent ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...